Nonprofit collecting handwritten letters to help seniors cope with isolation
Making seniors smile through handwritten letters. Itâs a simple action to help combat a serious problem â senior isolation.
and last updated 2021-07-01 23:06:18-04
Making seniors smile through handwritten letters. Itâs a simple action to help combat a serious problem â senior isolation.
In 2013, Jacob Cramer created the nonprofit Love For Our Elders, which collects handwritten letters from around the world and delivers them to care facilities.
âA letter is tangible. You can read it right now, you can save it for later, you can put it up on your bedside table, on a magnet, on your refrigerator. It s just so special to open a card that s just for you,â says Cramer.
Hillsborough plans to reverse impact fee jump tampabay.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tampabay.com Daily Mail and Mail on Sunday newspapers.
Search jobs Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
PREVENT-19 clinical trial expanded to assess the efficacy, safety and immunogenicity of NVX-CoV2373 for the prevention of COVID-19 in up to 3,000 12-17-year-old adolescents
President of Research and Development, Gregory Glenn, M.D., to provide update regarding the additional trial arm during World Vaccine Congress
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated a pediatric expansion of its Phase 3 clinical trial for NVX-CoV2373, the company s recombinant protein vaccine candidate against COVID-19. The additional arm of the ongoing PREVENT-19 pivotal trial will evaluate the efficacy, safety and immunogenicity of NVX-CoV2373 in up to 3,000 adolescents aged 12-17 across up to 75 sites in the United States.
Can Covid-19 vaccines be mixed-and-matched? Researchers are working to find out.
⋮
As more Covid-19 vaccines are authorized, scientists are exploring whether different vaccines can be safely and effectively mixed and matched, Carl Zimmer reports for the
New York Times an approach that if proven successful could not only overcome supply setbacks, but may also improve the efficacy of the vaccines.
Ongoing trials for mixing vaccines
Scientists have long explored the concept of vaccinating people with two different vaccines for the same disease, an approach known as a heterologous prime-boost. The theory is that, because each vaccine trains the immune system to respond in slightly different ways, two different vaccines in combination may produce more robust immunity than two doses of the same vaccine.